美国婴儿接种20价肺炎球菌结合疫苗的成本效果
本研究用基于人群的多队列决策分析马尔可夫模型,从社会与医疗系统视角评估美国婴儿接种20价肺炎球菌结合疫苗(PCV20)相比13价(PCV13)和15价(PCV15)疫苗10年内的健康与经济影响。结果显示,PCV20替代PCV13可避免大量侵袭性肺炎球菌疾病、肺炎、中耳炎和死亡,并产生净节省;与PCV15相比也显示净健康收益和净节省。
核心结论
- 婴儿接种PCV20预计较PCV13和PCV15进一步减少肺炎球菌疾病及相关医疗系统和社会成本。
研究设计与样本
- 研究采用基于人群的多队列决策分析马尔可夫模型,从社会与医疗系统视角评估美国婴儿接种PCV20在10年时间范围内的公共卫生影响和成本效果。
- 流行病学数据基于已发表研究和未发表的主动细菌核心监测系统(ABCs)数据,疫苗有效性基于PCV13有效性和PCV7效力研究,间接影响基于观察性研究,成本和负效用基于已发表数据。
- PCV20在单独情景中分别与PCV13和PCV15进行比较。
主要发现
- 避免的成本和病例很大比例归因于未接种疫苗的成人和老年人的间接效应。
- 从医疗系统视角,PCV20与PCV13和PCV15相比均为优势策略。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As of June 2023, two pneumococcal conjugate vaccines, 20- (PCV20) and 15- (PCV15) valent formulations, are recommended for US infants under a 3 + 1 schedule. This study evaluated the health and economic impact of vaccinating US infants with a new expanded valency PCV20 formulation. METHODS: A population-based, multi cohort, decision-analytic Markov model was developed to estimate the public health impact and cost-effectiveness of PCV20 from both societal and healthcare system perspectives over 10 years. Epidemiological data were based on published studies and unpublished Active Bacterial Core Surveillance System (ABCs) data. Vaccine effectiveness was based on PCV13 effectiveness and PCV7 efficacy studies. Indirect impact was based on observational studies. Costs and disutilities were based on published data. PCV20 was compared to both PCV13 and PCV15 in separate scenarios. RESULTS: Replacing PCV13 with PCV20 in infants has the potential to avert over 55,000 invasive pneumococcal disease (IPD) cases, 2.5 million pneumonia cases, 5.4 million otitis media (OM) cases, and 19,000 deaths across all ages over a 10-year time horizon, corresponding to net gains of 515,000 life years and 271,000 QALYs. Acquisition costs of PCV20 were offset by monetary savings from averted cases resulting in net savings of $20.6 billion. The same trend was observed when comparing PCV20 versus PCV15, with a net gain of 146,000 QALYs and $9.9 billion in net savings. A large proportion of the avoided costs and cases were attributable to indirect effects in unvaccinated adults and elderly. From a health-care perspective, PCV20 was also the dominant strategy compared to both PCV13 and PCV15. CONCLUSIONS: Infant vaccination with PCV20 is estimated to further reduce pneumococcal disease and associated healthcare system and societal costs compared to both PCV13 and PCV15.
引用
- Rozenbaum MH, Huang L, Perdrizet J, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants. Vaccine. 2024. PMID: 38191278. doi:10.1016/j.vaccine.2023.12.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。